Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

LUNG CANCER

Liquid biopsy for early stage lung cancer moves ever closer

Nature Reviews Clinical Oncology volume 17, pages 523–524 (2020)Cite this article

Subjects

Lung cancer screening is currently based only on low-dose CT scans; however, novel, more accessible methods that might improve uptake and adherence are eagerly awaited. New liquid biopsy approaches promise to revolutionize cancer screening. Herein, we discuss the opportunities and challenges associated with two such novel assays.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Liquid biopsy for early lung cancer detection.

References

  1. Shieh, Y. & Bohnenkamp, M. Low-dose CT scan for lung cancer screening: clinical and coding considerations. Chest 152, 204–209 (2017).

    Article  Google Scholar 

  2. Okereke, I. C., Nishi, S., Zhou, J. & Goodwin, J. S. Trends in lung cancer screening in the United States, 2016–2017. J. Thorac. Dis. 11, 873–881 (2019).

    Article  Google Scholar 

  3. Rolfo, C. et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. J. Thorac. Oncol. 13, 1248–1268 (2018).

    Article  Google Scholar 

  4. Abbosh, C., Birkbak, N. J. & Swanton, C. Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection. Nat. Rev. Clin. Oncol. 15, 577–586 (2018).

    Article  CAS  Google Scholar 

  5. Russo, A. et al. Liquid biopsy tracking of lung tumor evolutions over time. Expert Rev. Mol. Diagn. 19, 1099–1108 (2019).

    Article  CAS  Google Scholar 

  6. Chabon, J. J. et al. Integrating genomic features for non-invasive early lung cancer detection. Nature 580, 245–251 (2020).

    Article  CAS  Google Scholar 

  7. Liu, M. C. et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann. Oncol. 31, 745–759 (2020).

    Article  Google Scholar 

  8. Lennon, A. M. et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science https://doi.org/10.1126/science.abb9601 (2020).

    Article  PubMed  Google Scholar 

  9. Sozzi, G. et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J. Clin. Oncol. 32, 768–773 (2014).

    Article  Google Scholar 

  10. Zhang, L. et al. A high-performing plasma metabolite panel for early-stage lung cancer detection. Cancers (Basel) 12, E622 (2020).

    Article  Google Scholar 

Download references

Acknowledgements

We thank Umberto Malapelle and Diego de Miguel Perez for their helpful suggestions during manuscript preparation.

Author information

Authors and Affiliations

  1. Thoracic Oncology & Experimental Therapeutics Program, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA

    Christian Rolfo & Alessandro Russo

Authors
  1. Christian Rolfo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Rolfo.

Ethics declarations

Competing interests

C.R. has received speakers’ bureau from AstraZeneca and MSD, a research grant from the Lung Cancer Research Foundation–Pfizer, and research support from Guardant Health and Biomark; has an advisory board role with ARCHER, Inivata and Merck Serono; and has consulted for Mylan and Oncopass. A.R declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rolfo, C., Russo, A. Liquid biopsy for early stage lung cancer moves ever closer. Nat Rev Clin Oncol 17, 523–524 (2020). https://doi.org/10.1038/s41571-020-0393-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-020-0393-z

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer